EP4647125A2 — Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
Assigned to Bayer Healthcare LLC · Expires 2025-11-12 · 1y expired
What this patent protects
The present invention relates to a method for treating or preventing an angiogenic eye disorder, in a subject in need thereof, comprising administering to an eye of the subject, a single initial dose of about 8 mg or more of a VEGF antagonist, followed by one or more secondary do…
USPTO Abstract
The present invention relates to a method for treating or preventing an angiogenic eye disorder, in a subject in need thereof, comprising administering to an eye of the subject, a single initial dose of about 8 mg or more of a VEGF antagonist, followed by one or more secondary doses of about 8 mg or more of the VEGF antagonist, followed by one or more tertiary doses of about 8 mg or more of the VEGF antagonist; wherein each secondary dose is administered about 2 to 4 weeks after the immediately preceding dose; and wherein each tertiary dose is administered about 4, 8 or 12 weeks after the immediately preceding dose.
Drugs covered by this patent
- Acthar Gel (CORTICOTROPIN) · Mallinckrodt Ireland
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.